Skip to main content
Listen in: the latest news on Biosimilars! Listen to our new Coffee with ClearScript for the latest news on Biosimilars!

The clear choice in pharmacy benefit management.

Insights Archive

bottle of spilled pills

October 2, 2023

New Drug Spotlight: Arexvy, Abrysvo, and Beyfortus

In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.

Conceptual image of syringes wrapped in money

September 29, 2023

Insulin Update

Amidst growing public and government attention on insulin affordability, what do plan sponsors need to know as they plan coverage strategies in 2024 and beyond?

bottle of spilled pills

May 30, 2023

New Drug Spotlight: Amjevita

The launch of Amjevita, the first FDA-approved biosimilar for Humira, is big news for pharmacy benefit plan sponsors.

Drug Pipeline – Blue pills traveling through a sorting machine, a green pill stands out from the rest.

May 30, 2023

First in a new class

An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy?

Drug Pipeline – Blue pills traveling through a sorting machine, a yellow pill stands out from the rest.

May 30, 2023

Are you watching this?

Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials.

Drug Pipeline – Blue pills traveling through a sorting machine, a red pill stands out from the rest.

May 8, 2023

The most expensive medicine in the world

Remarkably, 94% of participants in the supporting study who received Hemgenix were able to discontinue use of intravenous FIX infusions. This is an important consideration since FIX infusion therapy can cost of approximately $500,000–$750,000 per year.